

## GCHP Medi-Cal Clinical Guidelines

### Hyaluronic Acid Derivatives

(Durolan<sup>TM</sup>, Euflexxa<sup>TM</sup>, Gel-One<sup>TM</sup>, Gelsyn-3<sup>TM</sup>,  
GenVisc 850<sup>TM</sup>, Hyalgan<sup>TM</sup>, Hymovis<sup>TM</sup>, Monovisc<sup>TM</sup>,  
Orthovisc<sup>TM</sup>, Supartz-FX<sup>TM</sup>, Synvisc<sup>TM</sup>, Synvisc-One<sup>TM</sup>,  
Triluron<sup>TM</sup>, TriVisc<sup>TM</sup>, Visco-3<sup>TM</sup>)

PA Criteria	Criteria Details
<b>Covered Uses (FDA Approved Indication)</b>	<p><i>Durolane, Euflexxa, Gelsyn-3, GenVisc 850, Hyalgan, Hymovis, Monovisc, Orthovisc, Supartz FX, Synvisc, Synvisc-One, Triluron, Trivisc, Visco-3:</i> Treatment of pain in osteoarthritis of the knee in patients who have failed nonpharmacologic treatment and simple analgesics (e.g., acetaminophen).</p> <p><i>Gel-One:</i> Treatment of pain in osteoarthritis of the knee in patients who have failed nonpharmacologic treatment, nonsteroidal anti-inflammatory drugs (NSAIDs) or simple analgesics, (e.g., acetaminophen).</p>
<b>Exclusion Criteria</b>	<p>Treatment for pain in the knee due to causes other than osteoarthritis, such as gout, rheumatoid arthritis.</p> <p>Treatment for pain management for area(s) other than knee.</p> <p>Active joint infection.</p> <p>Bleeding disorder.</p>
<b>Required Medical Information</b>	<p>Initial Therapy</p> <ul style="list-style-type: none"> <li>• Documented clinical diagnosis of osteoarthritis of the knee.</li> <li>• At least one course of physical therapy for knee osteoarthritis.</li> <li>• Documented failure, inadequate response, or intolerance to at least two out of the three below (e.g., i and ii; i and iii, or ii and iii): <ul style="list-style-type: none"> <li>i. Two oral or topical [e.g., oral non-steroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, or topical NSAIDS (e.g., diclofenac 1 percent gel)],</li> <li>ii. Acetaminophen,</li> <li>iii. One or more trial in the last 12 months of intra-articular steroid injections unless intolerant or contraindicated.</li> </ul> </li> </ul> <p>Continuation</p> <ul style="list-style-type: none"> <li>• Documentation of positive clinical outcome from previous use of hyaluronic acid derivative.</li> <li>• At least six-month interval from prior hyaluronic acid derivative use.</li> </ul>
<b>Age Restriction</b>	<p>18 years of age and older except Durolane, Synjoynt and Visco-3, 22 years of age and older</p> <p>18 - 21 years of age and older – check for CCS</p>



<b>Prescriber Restrictions</b>	Rheumatology, Orthopedics, and pain management.		
<b>Coverage Duration</b>	One treatment series per knee at intervals no more frequent than six months.		
<b>Other Criteria / Information</b>	<b>HCPCS</b>	<b>Description</b>	<b>Dosing, Units</b>
	J7318	Hyaluronan or derivative, for intra-articular injection, 1mg (Durolane <sup>TM</sup> )	60mg once (60 units per dose)
	J7320	Hyaluronan or derivative, for intra-articular injection, 1mg (GenVisc 850 <sup>TM</sup> )	25mg once weekly x five weeks (25 units per dose)
	J7321	Hyaluronan or derivative, for intra-articular injection, 1mg (Hyalgan <sup>TM</sup> )	20mg once weekly x five weeks (one unit per dose)
		Hyaluronan or derivative, for intra-articular injection, 1mg (Supartz FX <sup>TM</sup> )	25mg once weekly x five weeks (one unit per dose)
		Hyaluronan or derivative, for intra-articular injection, 1mg (Visco 3 FX <sup>TM</sup> )	25mg once weekly x three weeks (one unit per dose)
	J7322	Hyaluronan or derivative, for intra-articular injection, 1mg (HymovisFX <sup>TM</sup> )	24mg once weekly x two weeks (24 units per dose)
	J7323	Hyaluronan or derivative, for intra-articular injection, 1mg (Euflexxa <sup>TM</sup> )	20mg once weekly x three weeks (one unit per dose)
	J7325	Hyaluronan or derivative, for intra-articular injection, 1mg (Synvisc <sup>TM</sup> )	16mg once weekly x three weeks (16 units per dose)
		Hyaluronan or derivative, for intra-articular injection, 1mg (Synvisc-One <sup>TM</sup> )	48mg once (48 units per dose)
	J7326	Hyaluronan or derivative, for intra-articular injection, 1mg (Gel-One <sup>TM</sup> )	30mg once (one units per dose)
	J7327	Hyaluronan or derivative, for intra-articular injection, 1mg (Monovisc <sup>TM</sup> )	88mg once (one unit per dose)
	J7328	Hyaluronan or derivative, for intra-articular injection, 1mg (Gelsyn-3 <sup>TM</sup> )	16.8mg once weekly x three weeks (168 units per dose)
	J7329	Hyaluronan or derivative, for intra-articular injection, 1mg (Trivisc <sup>TM</sup> )	25mg once weekly x three weeks (25 units per dose)
	J7331	Hyaluronan or derivative, for intra-articular injection, 1mg (Synojoint <sup>TM</sup> )	20mg once weekly x three weeks (20 units per dose)



	J7332	Hyaluronan or derivative, for intra-articular injection, 1mg (Triluron <sup>TM</sup> )	20mg once weekly x three weeks (20 units per dose)
--	-------	--	---

STATUS	DATE REVISED	REVIEW DATE	APPROVED / REVIEWED BY	EFFECTIVE DATE
Created	8/5/2024	8/5/2024	Yoonhee Kim, Interim Director of Pharmacy Services	N/A
Approved	N/A	8/15/2024	Pharmacy & Therapeutics (P&T) Committee	3/1/2025